The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 340 participants.
Also called NCT07739160
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 340 participants
- Registry
-
NCT07739160
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07739160. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-29 (actual); primary completion 2027-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- HRS-4029
- Intervention (Drug)
- Placebo
- Lead sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Record details
- Record id
cardio:ct-nct07739160- Content hash
67fd2a05e28497b68e8601e62aae467420fa8befd5450c0edcec16e0eb47d89a